Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

<< Back to News

5/2/23 je Molnupiravir (Adults ONLY) Go-Live
June 1, 2023

From: "Jonathan Edwards" <jonathan.edwards@hhsys.org>
To: "Pharmacists" <allpharm@hhsys.org>
Sent: Tuesday, May 2, 2023 1:57:30 PM
Subject: Re: Molnupiravir (Adults ONLY) Go-Live Today
 
Pharmacists,

Starting today, the ID physicians can order molnupiravir for patients that are admitted with an incidental finding of COVID-19.
  • Per the EUA - Patients with mild-to-moderate COVID-19 who are at high risk of progression to severe disease admitted to the hospital for reasons other than COVID-19 may receive molnupiravir
The primary benefit of this medication is less drug/drug interactions, but that benefit comes at the cost of decreased efficacy when compared to other treatment options for COVID-19. Molnupravir is considered last line therapy and should only be used if other treatment options are not available or clinically inappropriate. The use of this medication is expected to be relatively low. 

Please see attached infographic as well as criteria for use document.

Let us know if you have any questions.






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved